Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

TNF-alpha antagonists / inhibitors

5

XVII.z Histoplamosis (reactivation)

2
Last update : 31/12/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Adalimumab
3
Etanercept
4
Golimumab
1
Infliximab
5

Publications

Case records of the Massachusetts General Hospital. Case 32-2014. A 78-year-old woman with chronic sore throat and a tonsillar mass.
The New England journal of medicine 2014 Oct 16;371;1535-43 2014 Oct 16
Hepatitis and pneumonitis during adalimumab therapy in Crohn disease: mind the histoplasmosis!
Arquivos de gastroenterologia 2014;51;73-6 2014
Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009.
BMC infectious diseases 2011 May 23;11;145 2011 May 23
Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.
Respiratory medicine 2006 Jul;100;1291-3 2006 Jul
Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.
American journal of respiratory and critical care medicine 2003 May 01;167;1279-82 2003 May 01
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Arthritis and rheumatism 2002 Oct;46;2565-70 2002 Oct
Reactivation of histoplasmosis after treatment with infliximab.
The American journal of medicine 2002 Jan;112;78 2002 Jan

Powered by

  • ^
  • Contact
  • Cookies
  • About